Ventricular Tachycardia — ED Management

Key Points

• Assume a regular wide-complex tachycardia is VT until proven otherwise.
• Instability is determined by perfusion, not by heart rate alone.
• Pulseless VT requires immediate defibrillation and CPR.
• Unstable VT with a pulse requires synchronized cardioversion.
• Stable monomorphic VT can be treated with IV antiarrhythmics under close monitoring and expert consultation.
• Avoid verapamil and other empiric AV nodal blockers in undifferentiated wide-complex tachycardia.
• Adenosine is only a diagnostic or therapeutic option for selected regular monomorphic wide-complex rhythms.
• Polymorphic VT and torsades require a different strategy, including unsynchronized shock when unstable and magnesium for torsades.
• Correct ischemia, potassium, magnesium, hypoxia, acidosis, and drug triggers.

Algorithm

1. Check pulse and assess blood pressure, mental status, shock, ischemic pain, and acute heart failure.
2. If pulseless, defibrillate and begin the shockable cardiac arrest algorithm.
3. If unstable with a pulse, perform synchronized cardioversion immediately.
4. If stable, obtain a 12-lead ECG and determine whether the rhythm is monomorphic or polymorphic.
5. Treat stable monomorphic VT with an appropriate IV antiarrhythmic and expert consultation.
6. Use adenosine only if the rhythm is regular and monomorphic and an SVT mechanism remains plausible.
7. Check and correct potassium, magnesium, ischemia, hypoxia, acidosis, and drug toxicity.
8. After conversion, admit and evaluate structural disease, ischemia, and need for electrophysiologic or ICD therapy.

Clinical Synopsis & Reasoning

Any regular wide-complex tachycardia should be presumed ventricular tachycardia until proven otherwise, particularly in an older patient or anyone with structural heart disease, prior myocardial infarction, cardiomyopathy, or known ventricular arrhythmia. Mistaking VT for supraventricular tachycardia with aberrancy and administering an AV nodal blocker such as verapamil can precipitate severe hypotension or arrest. The first diagnostic decision is therefore not the exact mechanism; it is whether the patient is unstable and whether the rhythm should be treated as VT.

Instability includes hypotension, altered mental status from poor perfusion, signs of shock, ischemic chest discomfort, or acute heart failure attributable to the tachycardia. A patient with a pulse and unstable monomorphic VT requires synchronized cardioversion without delaying for laboratory tests. Pulseless VT is cardiac arrest and requires immediate defibrillation, high-quality CPR, epinephrine, and the standard shockable-rhythm algorithm.

When the patient is stable, inspect the rhythm. Monomorphic VT has a relatively consistent QRS morphology beat to beat and commonly reflects a reentry circuit around scar. Polymorphic VT has changing QRS morphology and includes torsades de pointes when associated with a prolonged QT interval. Polymorphic VT is treated differently because synchronization is unreliable and recurrent torsades requires magnesium and correction of QT-promoting factors.

Search for precipitants in parallel: acute coronary ischemia, hypokalemia, hypomagnesemia, acidosis, hypoxia, drug toxicity, decompensated heart failure, myocarditis, and inherited arrhythmia syndromes. Obtain a 12-lead ECG during the arrhythmia if this does not delay therapy, and obtain another after conversion to look for ischemia, QT prolongation, Brugada pattern, preexcitation, or evidence of prior infarction.

Treatment Strategy & Disposition

For pulseless VT, defibrillate as soon as possible and follow the 2025 AHA cardiac arrest algorithm. Continue high-quality CPR, give epinephrine at recommended intervals, and consider amiodarone or lidocaine for shock-refractory VF/pVT. Treat reversible causes without interrupting defibrillation and CPR.

For unstable VT with a pulse, perform synchronized cardioversion. Sedation is desirable when the patient is conscious and blood pressure allows, but cardioversion should not be delayed in a rapidly deteriorating patient. If synchronization cannot be achieved and the patient is crashing, deliver an unsynchronized shock as for polymorphic VT or VF according to resuscitation practice.

For stable monomorphic wide-complex tachycardia, obtain expert consultation and use an IV antiarrhythmic strategy. Procainamide, amiodarone, or sotalol are established options depending on ventricular function, QT interval, blood pressure, and comorbidities. The AHA adult tachycardia algorithm lists procainamide infusion until suppression, hypotension, QRS widening, or a maximum dose, and amiodarone 150 mg over 10 minutes with repeat dosing and infusion when needed. Avoid procainamide in prolonged QT or decompensated heart failure. Avoid sotalol in prolonged QT. Adenosine can be considered only for a regular monomorphic wide-complex rhythm when the diagnosis is uncertain; it should not be used for irregular or polymorphic wide-complex tachycardia.

Correct potassium and magnesium, treat ischemia, stop QT-prolonging or proarrhythmic medications, and manage heart failure or toxicologic causes. Sustained VT generally warrants admission, cardiology/electrophysiology evaluation, and assessment for coronary disease, structural heart disease, and secondary-prevention ICD when appropriate.

Epidemiology / Risk Factors

• Sustained monomorphic VT is strongly associated with structural heart disease and prior myocardial scar.
• Patients with cardiomyopathy or reduced ejection fraction are at higher risk for recurrent VT and sudden death.
• Acute ischemia can trigger polymorphic VT or VF.
• Drug-induced QT prolongation and electrolyte depletion predispose to torsades rather than classic scar-mediated monomorphic VT.
• Sustained VT in a patient without known structural disease still requires evaluation for occult cardiomyopathy or inherited arrhythmia syndrome.

Investigations

Adjuncts

Pharmacology

Prognosis / Complications

• Hemodynamically unstable VT can rapidly deteriorate to cardiac arrest.
• Recurrent sustained VT often indicates significant structural heart disease and may require ICD therapy or ablation.
• Correcting reversible triggers lowers recurrence risk but does not eliminate risk from fixed myocardial scar.
• Patients with idiopathic VT in structurally normal hearts can have a better prognosis but still need specialist confirmation.
• Survival after pulseless VT depends heavily on immediate defibrillation and high-quality CPR.

Patient Education / Counseling

• Explain that sustained VT is not simply a fast heart rate and requires evaluation for heart disease and sudden-death risk.
• Review new or stopped medications that can affect QT interval or electrolytes.
• Seek emergency care for syncope, sustained palpitations, chest pain, or recurrent near-syncope.
• If an ICD is implanted, provide device-specific shock instructions and follow-up.
• Avoid driving until cardiology has addressed recurrence and local restrictions.
• Discuss adherence to heart-failure, ischemic-heart-disease, and electrolyte-management plans.

Notes

Wide-complex tachycardia is a setting in which diagnostic humility improves safety. Treating an uncertain rhythm as VT is generally safer than assuming SVT and giving a calcium-channel blocker. The immediate danger is hemodynamic deterioration, and therapy should follow the patient's perfusion status.

After conversion, the work is not finished. Sustained VT is often a marker of myocardial scar, cardiomyopathy, ischemia, or an inherited electrical disorder. Definitive management may include coronary treatment, heart-failure optimization, electrophysiology study, ablation, or ICD placement.

References

1. American Heart Association 2025 Adult Advanced Life Support — Link
2. AHA Adult Tachycardia With a Pulse Algorithm — Link